A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study)

Autor:	Cristina Cruz Zambrano, Susana Bezares, Juan de la Haba, Barbara Adamo, Santiago Gonzalez Santiago, Raquel Andrés, Montserrat Muñoz, Sonia Alonso Soler, Vanesa García, M Melé, Federico Rojo, Sebastian Moran Salama, Nuria Martin, M. J. Escudero, Manel Esteller, Sonia Servitja, Sara López-Tarruella, Rosalia Caballero, Jose Alejandro Perez-Fidalgo, Angel Guerrero-Zotano
Rok vydání:	2018
Předmět:	0301 basic medicine Oncology Cancer Research medicine.medical_specialty business.industry Advanced breast Cancer medicine.disease Olaparib Clinical trial 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine chemistry 030220 oncology & carcinogenesis Internal medicine Promoter methylation Medicine In patient skin and connective tissue diseases business Triple-negative breast cancer
Zdroj:	Journal of Clinical Oncology. 36:TPS1114-TPS1114
ISSN:	1527-7755 0732-183X
Popis:	TPS1114Background: Identification of targeted therapies for advanced triple negative breast cancer (TNBC) remains as an important clinical challenge. TNBC frequently shows BRCA dysfunction and 80% ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::99bbace4e77e4df6ebd4019dd23be59e https://doi.org/10.1200/jco.2018.36.15_suppl.tps1114 Zobrazit plný text záznamu